financetom
Business
financetom
/
Business
/
Update: TC Energy Appoints New CFO; National Bank Reviews Leadership Change
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: TC Energy Appoints New CFO; National Bank Reviews Leadership Change
Apr 3, 2024 8:10 AM

10:35 AM EDT, 04/03/2024 (MT Newswires) -- TC Energy Corp. ( TRP ) said Wednesday that Joel Hunter will step down as executive vice president and chief financial officer of the company to pursue another opportunity in the energy sector.

The board has tapped Sean O'Donnell to serve as its new executive vice president and CFO, effective May 15.

Hunter will remain with the company until July 1 to support the company's 2024 strategic priorities, including the intended spinoff of South Bow, and to ensure a smooth transition.

O'Donnell is currently serving as senior vice president of capital markets and corporate planning.

Meanwhile, National Bank said Wednesday while the change was unexpected, it does not expect the leadership change to impact the company's strategy or top priorities.

"While the change in CFO leadership is unexpected, we do not expect any immediate shift in the company's strategy or top priorities, including deleveraging the balance sheet with another near $2-3 billion of asset sales to be executed in 2024 (NBF: $4-5 billion) along with the spinoff of South Bow Corporation in H2 2024, together achieving its stated D/EBITDA target of 4.75x by year end," the analysts said.

National Bank has an outperform rating on the company and a C$58 price target.

The company's shares slipped near 0.8% on last look on Wednesday.

Price: 53.91, Change: -0.39, Percent Change: -0.72

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
United Therapeutics Insider Sold Shares Worth $5,112,335, According to a Recent SEC Filing
United Therapeutics Insider Sold Shares Worth $5,112,335, According to a Recent SEC Filing
Nov 13, 2025
04:38 PM EST, 11/13/2025 (MT Newswires) -- Paul A Mahon, Executive Vice President & General Counsel, on November 13, 2025, sold 11,000 shares in United Therapeutics ( UTHR ) for $5,112,335. Following the Form 4 filing with the SEC, Mahon has control over a total of 36,781 common shares of the company, with 36,781 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1082554/000123158925000010/xslF345X05/primarydocument.xml...
EV charging firm Nuvve's Q3 revenue falls 
EV charging firm Nuvve's Q3 revenue falls 
Nov 13, 2025
Overview * Nuvve Q3 2025 revenue fell 16.7% yr/yr to $1.6 mln * Net loss for Q3 2025 increased to $4.8 mln from $1.6 mln yr/yr * Company raised $5.6 mln through public offering and debt in Q3 2025 Outlook * Nuvve ( NVVE ) anticipates expanding its stationary battery business in North America, Europe, and Japan * Company focuses...
Huntington Ingalls Industries Insider Sold Shares Worth $4,815,900, According to a Recent SEC Filing
Huntington Ingalls Industries Insider Sold Shares Worth $4,815,900, According to a Recent SEC Filing
Nov 13, 2025
04:38 PM EST, 11/13/2025 (MT Newswires) -- Christopher D Kastner, Director, President & CEO, on November 12, 2025, sold 15,000 shares in Huntington Ingalls Industries ( HII ) for $4,815,900. Following the Form 4 filing with the SEC, Kastner has control over a total of 70,503 common shares of the company, with 2,264 shares held directly and 68,239 controlled indirectly....
Biopharmaceutical firm VistaGen's fiscal Q2 net loss widens
Biopharmaceutical firm VistaGen's fiscal Q2 net loss widens
Nov 13, 2025
Overview * VistaGen fiscal Q2 net loss widens to $19.4 mln from $13.0 mln year-over-year * R&D expenses increased to $15.9 mln, driven by PALISADE Program costs * Company expects PALISADE-3 Phase 3 trial results by year-end Outlook * VistaGen expects PALISADE-3 trial results by year-end 2025 * PALISADE-4 trial results anticipated in H1 2026 Result Drivers * R&D EXPENSES...
Copyright 2023-2026 - www.financetom.com All Rights Reserved